180 related articles for article (PubMed ID: 27491374)
1. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
[TBL] [Abstract][Full Text] [Related]
2. Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours.
Zandee WT; van Adrichem RC; Kamp K; Feelders RA; van Velthuysen MF; de Herder WW
Clin Endocrinol (Oxf); 2017 Aug; 87(2):165-170. PubMed ID: 28464233
[TBL] [Abstract][Full Text] [Related]
3. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial.
Jacobsen MB; Hanssen LE
J Intern Med; 1995 Mar; 237(3):269-75. PubMed ID: 7534331
[TBL] [Abstract][Full Text] [Related]
6. Small intestinal neuroendocrine tumors: prognostic factors and survival.
Bergestuen DS; Aabakken L; Holm K; Vatn M; Thiis-Evensen E
Scand J Gastroenterol; 2009; 44(9):1084-91. PubMed ID: 19572232
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
8. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract.
Rorstad O
J Surg Oncol; 2005 Mar; 89(3):151-60. PubMed ID: 15719376
[TBL] [Abstract][Full Text] [Related]
9. Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5-hydroxytryptophan intake.
Joy T; Walsh G; Tokmakejian S; Van Uum SH
Can J Gastroenterol; 2008 Jan; 22(1):49-53. PubMed ID: 18209781
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.
Tirosh A; Nilubol N; Patel D; Kebebew E
Endocr Pract; 2018 Aug; 24(8):710-717. PubMed ID: 30084688
[TBL] [Abstract][Full Text] [Related]
11. Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker.
Tohmola N; Itkonen O; Sane T; Markkanen H; Joenväärä S; Renkonen R; Hämäläinen E
Clin Chim Acta; 2014 Jan; 428():38-43. PubMed ID: 24211728
[TBL] [Abstract][Full Text] [Related]
12. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract][Full Text] [Related]
13. Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours.
van der Horst-Schrivers AN; Post WJ; Kema IP; Links TP; Willemse PH; Wymenga AN; de Vries EG
Eur J Cancer; 2007 Dec; 43(18):2651-7. PubMed ID: 17825550
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues.
Gut P; Ruchała M
Neuro Endocrinol Lett; 2019 Dec; 40(7-8):315-318. PubMed ID: 32304367
[TBL] [Abstract][Full Text] [Related]
15. [Determination of thresholds values for platelet serotonin and urinary 5-HIAA concentrations for the biological diagnosis of digestive neuroendocrine tumors].
Padelli M; Bruno C; Lemarchand J; Vourc'h P; Andres C; Blasco H; Benz-de Bretagne I
Ann Biol Clin (Paris); 2019 Apr; 77(2):161-168. PubMed ID: 30998196
[TBL] [Abstract][Full Text] [Related]
16. BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.
Mirakhur B; Pavel ME; Pommier RF; Fisher GA; Phan AT; Massien C; Liyanage N; Lowenthal SP; Vinik AI
Endocr Pract; 2018 Aug; ():. PubMed ID: 30084687
[TBL] [Abstract][Full Text] [Related]
17. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.
Rindi G; Falconi M; Klersy C; Albarello L; Boninsegna L; Buchler MW; Capella C; Caplin M; Couvelard A; Doglioni C; Delle Fave G; Fischer L; Fusai G; de Herder WW; Jann H; Komminoth P; de Krijger RR; La Rosa S; Luong TV; Pape U; Perren A; Ruszniewski P; Scarpa A; Schmitt A; Solcia E; Wiedenmann B
J Natl Cancer Inst; 2012 May; 104(10):764-77. PubMed ID: 22525418
[TBL] [Abstract][Full Text] [Related]
18. Determination of urinary 5-hydroxyindoleacetic acid as a metabolomics in gastric cancer.
Mokhtari M; Rezaei A; Ghasemi A
J Gastrointest Cancer; 2015 Jun; 46(2):138-42. PubMed ID: 25761643
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes.
De Block CE; Colpin G; Thielemans K; Coopmans W; Bogers JJ; Pelckmans PA; Van Marck EA; Van Hoof V; Martin M; De Leeuw IH; Bouillon R; Van Gaal LF
Diabetes Care; 2004 Jun; 27(6):1387-93. PubMed ID: 15161793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
